Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Onyx Earnings Top Analysts’ Estimates on Medicine Sales

Onyx Pharmaceuticals Inc., a maker cancer drugs, reported a fourth-quarter loss that was less than analysts’ estimates as sales of newly approved therapies rose faster than expected.

Onyx reported a fourth-quarter net loss of $42.9 million, or 64 cents a share, compared with net income of $216.7 million, or $3.16, a year earlier, the South San Francisco, California-based company said today in a statement. The loss excluding one-time items of 36 cents topped by 38 cents the average of 14 analysts’ estimates compiled by Bloomberg.

Onyx won approval for two therapies last year, Kyprolis, for the blood cancer multiple myeloma, and Stivarga, for advanced-colorectal cancer. The company’s third medicine, Nexavar, a treatment for kidney and liver cancer developed with Bayer AG, reached $1 billion in sales in 2011.

Onyx said 2012 revenue was $362.2 million. Analysts had expected $347.6 million, according to data compiled by Bloomberg. Sales of Kyprolis reached $64 million for the year, while analysts estimated $48 million.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.